Literature DB >> 18340076

Diagnosis and treatment of prostate cancer: summary of NICE guidance.

John Graham1, Mark Baker, Fergus Macbeth, Victoria Titshall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18340076      PMCID： PMC2267985          DOI： 10.1136/bmj.39498.525706.AD

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  25 in total

1.  Population-based study of grade progression in patients who harboured Gleason 3 + 3.

Authors:  Fanny Sampurno; Arul Earnest; Jeremy Millar; Mark Frydenberg; Declan Murphy; Warwick Delprado; Sue Evans
Journal:  World J Urol       Date:  2017-05-12       Impact factor: 4.226

2.  Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells.

Authors:  Zhenghui Guo; Hai Huang; Lexiang Zeng; Tao Du; Kewei Xu; Tianxin Lin; Chun Jiang; Wen Dong; Yi Cao; Jieqing Chen; WeiDe Zhong; Jian Huang
Journal:  Med Oncol       Date:  2011-09       Impact factor: 3.064

3.  The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.

Authors:  Timothy J Wilt
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

4.  Pre-treatment risk stratification of prostate cancer patients: A critical review.

Authors:  George Rodrigues; Padraig Warde; Tom Pickles; Juanita Crook; Michael Brundage; Luis Souhami; Himu Lukka
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

5.  The association of level of practical experience in transrectal ultrasonography guided prostate biopsy with its diagnostic outcome.

Authors:  S Tadtayev; A Hussein; L Carpenter; N Vasdev; G Boustead
Journal:  Ann R Coll Surg Engl       Date:  2016-09-23       Impact factor: 1.891

6.  Percutaneous MR-guided whole-gland prostate cancer cryoablation: safety considerations and oncologic results in 30 consecutive patients.

Authors:  Pierre De Marini; Roberto Luigi Cazzato; Julien Garnon; Thibault Tricard; Guillaume Koch; Georgia Tsoumakidou; Nitin Ramamurthy; Hervé Lang; Afshin Gangi
Journal:  Br J Radiol       Date:  2019-04-09       Impact factor: 3.039

7.  Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population.

Authors:  Mark A Rochester; Nora Pashayan; Fiona Matthews; Andrew Doble; John McLoughlin
Journal:  BMC Urol       Date:  2009-07-16       Impact factor: 2.264

8.  High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.

Authors:  H U Ahmed; E Zacharakis; T Dudderidge; J N Armitage; R Scott; J Calleary; R Illing; A Kirkham; A Freeman; C Ogden; C Allen; M Emberton
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

Review 9.  Challenges in assessing solid tumor responses to immunotherapy.

Authors:  Louis F Chai; Ethan Prince; Venu G Pillarisetty; Steven C Katz
Journal:  Cancer Gene Ther       Date:  2019-12-11       Impact factor: 5.987

10.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

Authors:  Elena Castro; Chee Goh; David Olmos; Ed Saunders; Daniel Leongamornlert; Malgorzata Tymrakiewicz; Nadiya Mahmud; Tokhir Dadaev; Koveela Govindasami; Michelle Guy; Emma Sawyer; Rosemary Wilkinson; Audrey Ardern-Jones; Steve Ellis; Debra Frost; Susan Peock; D Gareth Evans; Marc Tischkowitz; Trevor Cole; Rosemarie Davidson; Diana Eccles; Carole Brewer; Fiona Douglas; Mary E Porteous; Alan Donaldson; Huw Dorkins; Louise Izatt; Jackie Cook; Shirley Hodgson; M John Kennedy; Lucy E Side; Jacqueline Eason; Alex Murray; Antonis C Antoniou; Douglas F Easton; Zsofia Kote-Jarai; Rosalind Eeles
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.